Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).

Kate Ida Lathrop,Virginia G. Kaklamani,Andrew Brenner,Rong Li,Alia Nazarullah,Sarah Hackman,Courtney Thomas,Jonathan A. L. Gelfond,Marisa Rodriguez,Richard M Elledge

Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).

2020

Kate Ida Lathrop
Virginia G. Kaklamani
Andrew Brenner
Rong Li
Alia Nazarullah
Sarah Hackman
Courtney Thomas
Jonathan A. L. Gelfond
Marisa Rodriguez
Richard M Elledge

560Background: Patients with TNBC breast cancer have inferior treatment outcomes compared to other breast cancer subtypes and targeted therapies are lacking. S-equol is a novel oral Estrogen Recept...

Keywords:

Estrogen receptor beta
Estrogen
Oncology
Triple-negative breast cancer
(S)-Equol
in patient
Breast cancer
Internal medicine
Pathology
Agonist
Medicine
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations